Table 3.
Treatment Effect of Maraviroc, Weighted for Control Treatment, on Markers of Inflammation, Platelet and Monocyte Activation, Microbial Translocation, Vascular Homeostasis, and Preclinical Atherosclerosis
| Variables | Mean Change, SD | P |
|---|---|---|
| hsCRP, mg/L | –6.39 ± 29 | .888 |
| IL6, pg/mL | –5.0 ± 24 | .324 |
| D-Dimer, ng/mL | 1.3 ± 32 | .525 |
| sCD14, ng/mL | 786 ± 3924 | .944 |
| sCD163, ng/mL | 63.0 ± 624 | .231 |
| MCP-1, pg/mL | –20.6 ± 102 | .101 |
| LBP, ng/mL | –1577 ± 7445 | .573 |
| sVCAM, ng/mL | 90.3 ± 389 | .491 |
| Platelets/leukocyte aggregates, % | –3.2 ± 4.6 | .013 |
| Platelet-derived microparticles, n/µL | –14765 ± 35573 | .132 |
| EMP, n/µL | –311 ± 472 | <.001 |
| EPC, n/mL | 40 ± 192 | .014 |
| EMP/EPC ratio | –0.22 | <.001 |
| Tang, n/mL | 13 ± 474 | .833 |
| Brachial artery diameter, mm | 0.02 ± 0.22 | .600 |
| bFMD, % | 2.6 ± 3.0 | .002 |
| cfPWV, m/s | –1.0 ± 1.6 | .022 |
| cIMT, mm | –0.09 ± 0.18 | .038 |
Change was measured as the difference of the variable responses in the treatment orders as follows: (response/2 – response/1) in the AB order and (response/1 – response/2) in the BA order.
Abbreviations: bFMD, brachial flow-mediated dilation; cfPWV, carotid-femoral pulse wave velocity; cIMT, carotid intima-media thickness; EMP, endothelial microparticle; EPC, endothelial microparticle; HsCRP, high-sensitivity C-reactive protein; IL6, interleukin-6; LBP, lipopolysaccharide binding protein; MCP, monocyte chemotactic protein 1; sVCAM, soluble vascular cell adhesion molecule-1; Tang, angiogenic T cell.